Leuphasyl

Leuphasyl is designed to activate delta-opioid receptors expressed in skin keratinocytes, sensory nerve endings, and sebaceous glands. Opioid receptor activation in skin modulates neuropeptide release (substance P, cgrp/" class="wiki-internal-link">CGRP) from sensory nerves, reducing neurogenic inflammation and pain-signaling cascades that contribute to inflammatory processes. The claim is that this reduces the facial muscle tension triggered by habitual expressions, complementary to the SNAP-23 mechanism of argireline/" class="wiki-internal-link">argireline.

Argireline (Acetyl Hexapeptide-3) inhibits SNARE complex formation to reduce acetylcholine-mediated muscle contraction from the nerve terminal side. Leuphasyl is proposed to act complementarily by reducing the sensory trigger (pain/tension signal) that initiates muscle contraction. Combined use at lower concentrations of each ingredient is claimed to produce greater wrinkle reduction than either alone, allowing lower concentrations of each peptide without sacrificing efficacy.

Lipotec S.A. (developer) has published in vitro data showing leuphasyl reduces enkephalin/" class="wiki-internal-link">enkephalin degradation in skin models and modulates neuropeptide release in sensory neuron cultures. A 4-week clinical use study (n=20) using optical profilometry showed measurable reduction in crow's feet depth compared to vehicle. These are cosmetic claim studies, not rigorous clinical trials, and are not peer-reviewed in the same manner as pharmaceutical research.

Manufacturer studies combining leuphasyl with argireline (SNAP-8, Acetyl Octapeptide-3) at 4% total peptide claim up to 63% reduction in wrinkle depth after 28 days. These studies use standardized silicone replicas of periorbital skin and quantitative profilometry. Independent validation is limited and consumer outcomes vary significantly with formulation, skin condition, and individual biology.